![PDF) Utility of dermoscopy in nail psoriasis: Its correlation with the Nail Psoriasis Severity Index (NAPSI) and psoriatic arthritis PDF) Utility of dermoscopy in nail psoriasis: Its correlation with the Nail Psoriasis Severity Index (NAPSI) and psoriatic arthritis](https://www.researchgate.net/profile/Manjunath-Shenoy/publication/333574833/figure/tbl3/AS:765695994388482@1559567559231/Correlation-of-dermoscopic-features-with-grades-of-NAPSI_Q320.jpg)
PDF) Utility of dermoscopy in nail psoriasis: Its correlation with the Nail Psoriasis Severity Index (NAPSI) and psoriatic arthritis
![Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology](https://www.jrheum.org/content/jrheum/44/4/519/F4.large.jpg)
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology
![The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/eadc8199-9366-4580-b937-289c4d2d9003/gr1_lrg.jpg)
The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology
![Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0190962217322624-gr5.jpg)
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect
![Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0190962217322624-gr3.jpg)
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect
![Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-022-00746-6/MediaObjects/13555_2022_746_Fig2_HTML.png)
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink
![Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs | The Journal of Rheumatology Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs | The Journal of Rheumatology](https://www.jrheum.org/content/jrheum/48/8/1208/F3.large.jpg)
Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs | The Journal of Rheumatology
![Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - Journal of the American Academy of Dermatology Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3ae0776c-72b8-4746-afdb-595b0cf33db5/gr4_lrg.jpg)
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - Journal of the American Academy of Dermatology
![Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-022-00746-6/MediaObjects/13555_2022_746_Fig3_HTML.png)